Delivery Order SPE2DB24D2011-SPE2DB25FBPTA

Award Date 1/8/25
Potential Completion Date 1/9/25
Potential Value $2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 30 mg capsules. The contract has a ceiling value of $1,724.00 and an ultimate completion date of March 24, 2023. The contract is a firm fixed-price, delivery order contract, and there is no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 50 mg capsules. The contract has a ceiling value of $1,795.91 and a completion date of January 3, 2025. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 40 mg capsules. The firm-fixed-price contract has a ceiling value of $1,069.14 and a period of performance through January 25, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 20 mg capsules. The contract has a ceiling value of $1,165.58 and a completion date of January 7, 2025. It is a firm-fixed-price contract and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 20 mg capsules. The contract has a ceiling value of $1,246.34 and runs through January 9, 2025. It is a firm-fixed-price delivery order contract, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Vyvanse 40 mg capsules. The contract has a ceiling value of $9,227.86 and a performance period ending on August 8, 2024. It is a firm-fixed-price contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 20mg capsules. The $2,675.40 fixed-price contract has a completion date of December 12, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, generic drugs,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 50 mg capsules. The $3,847.73 firm fixed-price contract has a completion date of November 15, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical for a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 30 mg capsules. The contract is a firm fixed-price delivery order with a ceiling value of $9,680.28 and an ultimate completion date of August 28, 2024. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which serves as a primary...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 50 mg capsules. The contract has a ceiling value of $1,359.23 and runs through March 2024. It is a firm fixed-price delivery order contract, with no set-aside designation indicated. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
  • SPE2DB24D2011
    Indefinite Delivery Contract
  • SPE2DB24D2011-SPE2DB25FBPTA
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 70mg capsules. The contract has an ultimate completion date of January 9, 2025 and a ceiling value of $2,043.85. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.

Generated 4/9/25, 9:49 AM